{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T07:52:36Z","timestamp":1789199556651,"version":"build-2803163510"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Belantamab mafodotin (belamaf), an antibody-drug conjugate approved for the treatment of relapsed and refractory multiple myeloma (RRMM), is an anti B-cell maturation antigen (BCMA) agent. DREAMM-1, a first in-human trial of belamaf, reported several ocular toxicities requiring dose adjustments, dose delays and treatment discontinuations. In DREAMM-1, 53% of patients in part-1 and 63% of patients in part-2 had ocular toxicity. Similarly, 73% of patients in DREAMM-2 had keratopathy (71% in 2.5 mg\/kg <jats:italic>versus<\/jats:italic> 75% in 3.4 mg\/kg) with the most common symptoms being blurred vision and dry eyes. Ocular toxicity of belamaf is attributed to microtubule-disrupting monomethylauristatin-F (MMAF), a cytotoxic payload of the drug that causes an off-target damage to the corneal epithelial cells. Ocular adverse events (AEs) of belamaf are more frequent at higher doses compared with lower doses. Higher belamaf dose, history of dry eyes and soluble BCMA are associated with increased risk of corneal toxicity. Absence of ocular symptoms does not exclude the possibility of belamaf-induced ocular toxicity, so patients need slit lamp and Snellen visual acuity testing to detect microcytic-like epithelial changes and visual decline. Corticosteroid eyes drops for 4-7 days prior to belamaf dose do not prevent ocular AEs and may cause steroid-related AEs instead. Keratopathy and Visual Acuity scale (<jats:italic>KVA<\/jats:italic>) is recommended to document the severity of belamaf-induced ocular toxicity and make treatment adjustments. Management of toxicity includes dosage modifications, treatment interruption or discontinuations and preservative-free artificial tears along with close ophthalmology and hematology-oncology follow-ups.<\/jats:p>","DOI":"10.3389\/fonc.2021.678634","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T07:26:06Z","timestamp":1620717966000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":82,"title":["Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma"],"prefix":"10.3389","volume":"11","author":[{"given":"Ahsan","family":"Wahab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Rafae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeel","family":"Masood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Ehsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Khakwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aqsa","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,11]]},"reference":[{"key":"B1","unstructured":"FDA Granted Accelerated Approval to Belantamab Mafodotin-Blmf for Multiple Myeloma2020"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015958","article-title":"Hodgkin Lymphoma Cells Express TACI and BCMA Receptors and Generate Survival and Proliferation Signals in Response to BAFF and APRIL","volume":"109","author":"Chiu","year":"2007","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1309417110","article-title":"Lin K-I. B-Cell Maturation Antigen is Modified by a Single N-Glycan Chain That Modulates Ligand Binding and Surface Retention","volume":"110","author":"Huang","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA Promote Human Multiple Myeloma Growth and Immunosuppression in the Bone Marrow Microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-Cell Maturation Antigen With GSK2857916 Antibody\u2013Drug Conjugate in Relapsed or Refractory Multiple Myeloma (BMA117159): A Dose Escalation and Expansion Phase 1 Trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-019-0196-6","article-title":"Antibody\u2013Drug Conjugate, GSK2857916, in Relapsed\/Refractory Multiple Myeloma: An Update on Safety and Efficacy From Dose Expansion Phase I Study","volume":"9","author":"Trudel","year":"2019","journal-title":"Blood Cancer J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma (DREAMM-2): A Two-Arm, Randomised, Open-Label, Phase 2 Study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-017-0520-6","article-title":"Clinical Toxicity of Antibody Drug Conjugates: A Meta-Analysis of Payloads","volume":"36","author":"Masters","year":"2018","journal-title":"Invest New Drugs"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-014-0151-0","article-title":"Phase I Dose-Escalation Study of SGN-75 in Patients With CD70-Positive Relapsed\/Refractory Non-Hodgkin Lymphoma or Metastatic Renal Cell Carcinoma","volume":"32","author":"Tannir","year":"2014","journal-title":"Invest New Drugs"},{"key":"B10","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/jop.2015.0064","article-title":"Ocular Adverse Events Associated With Antibody\u2013Drug Conjugates in Human Clinical Trials","volume":"31","author":"Eaton","year":"2015","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal Epithelial Findings in Patients With Multiple Myeloma Treated With Antibody\u2013Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-015-1657-7","article-title":"Current ADC Linker Chemistry","volume":"32","author":"Jain","year":"2015","journal-title":"Pharm Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.963.963","article-title":"Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Acute Leukemia and Highly Aggressive Lymphoma","volume":"124","author":"Fathi","year":"2014","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.ophtha.2020.07.047","article-title":"Belantamab Mafotodin-Induced Epithelial Keratopathy Masquerading Myopic Surgery","volume":"127","author":"Rousseau","year":"2020","journal-title":"Ophthalmology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14429","article-title":"Identification of Novel Macropinocytosis Inhibitors Using a Rational Screen of Food and Drug Administration-Approved Drugs","volume":"175","author":"Lin","year":"2018","journal-title":"Br J Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139698","article-title":"Exposure-Response (E-R) for Ocular Safety Endpoints for Belantamab Mafodotin (Belamaf), a B-Cell Maturation Antigen (BCMA)-Targeting Agent, in Patients With Relapsed\/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study","volume":"136","author":"Ferron-Brady","year":"2020","journal-title":"Blood"},{"key":"B17","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.02017"},{"key":"B18","volume-title":"Oncologic Drugs Advisory Committee (ODAC) Meeting), Belantamab Mafodotin, Combined FDA and Applicant ODAC Briefing Document.","year":"2020"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25382","article-title":"Bortezomib Ocular Toxicities: Outcomes With Ketotifen","volume":"94","author":"Dennis","year":"2019","journal-title":"Am J Hematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139315","article-title":"Ocular Health of Patients With Relapsed\/Refractory Multiple Myeloma (RRMM): Baseline Data From the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf)","volume":"136","author":"Popat","year":"2020","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1182\/blood-2020-139332","article-title":"DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination With Bortezomib\/Dexamethasone (Bordex) in Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"136","author":"Popat","year":"2020","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139395","article-title":"Patient-Reported Experiences During and Following Treatment With Belantamab Mafodotin (Belamaf) for Relapsed\/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study","volume":"136","author":"Eliason","year":"2020","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-140013","article-title":"DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients With Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"136","author":"Popat","year":"2020","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2474","article-title":"Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody\u2013Drug Conjugate Mirvetuximab Soravtansine","volume":"25","author":"Matulonis","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.3324\/haematol.2019.235937","article-title":"Characterization of Response and Corneal Events With Extended Follow-Up After Belantamab Mafodotin (GSK2857916) Monotherapy for Patients With Relapsed Multiple Myeloma: A Case Series From the First-Time-in-Human Clinical Trial","volume":"105","author":"Popat","year":"2020","journal-title":"haematologica"},{"key":"B26","doi-asserted-by":"publisher","first-page":"S477","DOI":"10.1016\/j.jval.2020.08.446","article-title":"PCN309 Methodology for Evaluating Meaningful Change Thresholds in Patient-Reported Outcome (PRO) Measures for Corneal Events in Patients With Relapsed\/Refractory Multiple Myeloma (RRMM) Receiving Single-Agent Belantamab Mafodotin (BELAMAF)","volume":"23","author":"Eliason","year":"2020","journal-title":"Value Health"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e20531","article-title":"DREAMM-1: Patient Perspectives From the First-in-Human Study of Single-Agent Belantamab Mafodotin for Relapsed and Refractory Multiple Myeloma (RRMM)","volume":"38","author":"Eliason","year":"2020","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720979813","article-title":"The Role of Belantamab Mafodotin for Patients With Relapsed and\/or Refractory Multiple Myeloma","volume":"11","author":"Becnel","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e000734","DOI":"10.1136\/jitc-2020-000734","article-title":"The Society for Immunotherapy of Cancer Consensus Statement on Immunotherapy for the Treatment of Multiple Myeloma","volume":"8","author":"Shah","year":"2020","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.678634\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T07:26:15Z","timestamp":1620717975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.678634\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,11]]},"references-count":29,"alternative-id":["10.3389\/fonc.2021.678634"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.678634","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,11]]},"article-number":"678634"}}